Plasma-free C1-INH acute treatment from day 1
Onset of HAE attacks typically occurs during childhood or adolescence**.
In paediatric HAE patients, one dose*** of RUCONEST®
Successfully treated 96% of HAE attacks in children aged 5 to 14 years10
n=20 (70 of a total of 73 attacks)
Raised C1-INH levels back to normal**** in 90% of children aged 5 to 14 years7
n=20 (18 of a total of 20 patients)
Raises C1-INH levels back to normal**** in ≈91% of children aged 2 to <5 years7
As shown on a population PK model.
* RUCONEST® is indicated for treatment of acute angioedema attacks in adults, adolescents, and children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency.
** Mean age of symptom onset in HAE patients: 4‐14 years.10
*** Dosing of RUCONEST® is body weight dependent and one dose is, therefore, based on patient weight as follows; <42kg = up to 1 vial, 42-84 kg = 50 U/kg (up to 2 vials), >84kg = 2 vials. In children an additional dose may be administered if the patient has not responded adequately after 60 minutes.
**** Above the lower limit of the normal range as observed in healthy individuals(0.7-1.3 U/ml).4
○ No evidence of C1‐INH neutralizing antibodies (inhibitors) has been observed in children aged 5 to 14 years treated with rhC1‐INH.10
‡ Figure is rounded based upon 98.6% (Feussner6) and 98.7% (van Veen5); there are virtually no host related impurities.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.